{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:49:30Z","timestamp":1790732970192,"version":"4.1.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Research Foundation Postgraduate Scholarship","award":["MND 210503598667"],"award-info":[{"award-number":["MND 210503598667"]}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","award":["R01AI152142"],"award-info":[{"award-number":["R01AI152142"]}],"id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K43TW011437"],"award-info":[{"award-number":["K43TW011437"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24AI150349"],"award-info":[{"award-number":["K24AI150349"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tenofovir alafenamide (TAF) is a key component of many fixed-dose combinations used to treat HIV. There are limited data on the pharmacokinetics of plasma TAF, tenofovir (TFV), or intracellular tenofovir diphosphate (TFV-DP), among people with HIV (PWH) and tuberculosis (TB) who are taking rifampicin-based TB treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants in the intervention arm of the INSIGHT trial (NCT04734652) receiving bictegravir\/emtricitabine\/TAF (BIC\/FTC\/TAF 50\/200\/25\u2005mg) were enrolled into the semi-intensive pharmacokinetic substudy. BIC\/FTC\/TAF was administered twice-daily during rifampicin-based TB treatment (\u223c24 weeks) and once-daily thereafter. Plasma (TAF\/TFV) and dried blood spot samples (TFV-DP) were collected at weeks 4 and 12 (predose, 1, 2, 4, 6, and 8\u201312\u2005hours postdose) during TB treatment and at week 32 (predose, 1, 2, 4, 6\u20138 and 24\u201325\u2005hours postdose) post-TB treatment. Pharmacokinetic parameters were determined using noncompartmental analysis. Clinical and safety data were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 43 participants enrolled; median (IQR) age and weight were 35 (30\u201339) years and 58 (52\u201365) kg; 77% were male. Geometric least square mean ratios (90% CI) at week 12 (twice-daily TAF) relative to week 32 (once-daily TAF) for TAF AUC0-4, TFV, and TFV-DP AUC0-24 were 1.55 (1.13\u20132.13), 1.24 (1.07\u20131.44), and 1.32 (1.13\u20131.53), respectively. At week 24, 95% of participants achieved viral suppression, with no treatment-related serious adverse events or drug discontinuations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Twice-daily TAF was safe and efficacious and achieved similar exposures of intracellular TFV-DP in PWH taking rifampicin for TB compared to once-daily TAF taken alone. These data support the use of TAF in a fixed-dose combination of BIC\/FTC\/TAF during rifampicin-containing TB treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf732","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T12:30:21Z","timestamp":1767011421000},"page":"e720-e727","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir\/Emtricitabine\/Tenofovir Alafenamide and Rifampicin"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2035-0935","authenticated-orcid":false,"given":"Emmanuella Chinonso","family":"Osuala","sequence":"first","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu-Natal , Durban ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5921-7904","authenticated-orcid":false,"given":"Ivan Nicholas","family":"Nkuhairwe","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Cape Town ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2170-6312","authenticated-orcid":false,"given":"Marothi Peter","family":"Letsoalo","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu-Natal , Durban ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8874-6661","authenticated-orcid":false,"given":"Kogieleum","family":"Naidoo","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu-Natal , Durban ,","place":["South Africa"]},{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), South African Medical Research Council (SAMRC)-CAPRISA-TB-HIV Pathogenesis and Treatment Research Unit, University of KwaZulu-Natal Nelson R Mandela School of Medicine , Durban ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8892-2904","authenticated-orcid":false,"given":"Rubeshan","family":"Perumal","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu-Natal , Durban ,","place":["South Africa"]},{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), South African Medical Research Council (SAMRC)-CAPRISA-TB-HIV Pathogenesis and Treatment Research Unit, University of KwaZulu-Natal Nelson R Mandela School of Medicine , Durban ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3261-0711","authenticated-orcid":false,"given":"James F","family":"Rooney","sequence":"additional","affiliation":[{"name":"Medical Affairs, Gilead Sciences , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9070-8699","authenticated-orcid":false,"given":"Lubbe","family":"Wiesner","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Cape Town ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5769-8150","authenticated-orcid":false,"given":"Roeland E","family":"Wasmann","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Cape Town ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7494-079X","authenticated-orcid":false,"given":"Paolo","family":"Denti","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Cape Town ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9013-5256","authenticated-orcid":false,"given":"Kelly E","family":"Dooley","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center , Nashville, Tennessee ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9550-9501","authenticated-orcid":false,"given":"Anushka","family":"Naidoo","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu-Natal , Durban ,","place":["South Africa"]},{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), South African Medical Research Council (SAMRC)-CAPRISA-TB-HIV Pathogenesis and Treatment Research Unit, University of KwaZulu-Natal Nelson R Mandela School of Medicine , Durban ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the INSIGHT Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushka","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kogieleum","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Dorse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubeshan","family":"Perumal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Resha","family":"Boodhram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Busisiwe","family":"Ntsalaze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiksha","family":"Byroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellisha","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anokhee","family":"Leela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavna","family":"Maharaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nompumelelo","family":"Zungu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phindile","family":"Msomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Shozi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhamoney","family":"Narasimmulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nokuzola","family":"Cwazibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesperi","family":"Venter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saras","family":"Pather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nokwanda","family":"Depargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silindile","family":"Tenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patience","family":"Mbatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marothi","family":"Letsoalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mxolisi","family":"Mahlangu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Samsunder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zanele","family":"Mchunu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avanthi","family":"Moodley-Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lungile","family":"Maphumulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adejumoke","family":"Abiose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuella Chinonso","family":"Osuala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"2026043013145408000_ciaf732-B1","author":"Joint United Nations Programme on HIV\/AIDS (UNAIDS)"},{"key":"2026043013145408000_ciaf732-B2","author":"World Health Organization"},{"key":"2026043013145408000_ciaf732-B3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/14740338.2020.1694901","article-title":"Safety implications of combined antiretroviral and anti-tuberculosis drugs","volume":"19","author":"Cerrone","year":"2020","journal-title":"Exp Opin Drug Safety"},{"key":"2026043013145408000_ciaf732-B4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/QAD.0000000000001744","article-title":"Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide","volume":"32","author":"Podany","year":"2018","journal-title":"AIDS"},{"key":"2026043013145408000_ciaf732-B5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/QAI.0000000000000225","article-title":"Tenofovir alafenamide vs. Tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study","volume":"67","author":"Sax","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026043013145408000_ciaf732-B6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/QAI.0000000000000618","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor\u2013based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study","volume":"69","author":"Mills","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026043013145408000_ciaf732-B7","volume-title":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach","author":"World Health Organization","year":"2021"},{"key":"2026043013145408000_ciaf732-B8","doi-asserted-by":"crossref","first-page":"103937","DOI":"10.1016\/j.meegid.2019.103937","article-title":"Evolution of rifampicin treatment for tuberculosis","volume":"74","author":"Grobbelaar","year":"2019","journal-title":"Infect Genet Evol"},{"key":"2026043013145408000_ciaf732-B9","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","article-title":"Pharmacokinetic interactions with rifampicin: clinical relevance","volume":"42","author":"Niemi","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"2026043013145408000_ciaf732-B10","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/jac\/dkz068","article-title":"Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide","volume":"74","author":"Cerrone","year":"2019","journal-title":"J Antimicrobial Chemother"},{"key":"2026043013145408000_ciaf732-B11","author":"Custodio"},{"key":"2026043013145408000_ciaf732-B12","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.jiph.2023.10.011","article-title":"The clinical impact of rifampicin-based anti-TB therapy and tenofovir alafenamide-containing ARV regimen drug interaction in people living with HIV: case series report","volume":"16","author":"Mohzari","year":"2023","journal-title":"J Infect Public Health"},{"key":"2026043013145408000_ciaf732-B13","author":"Mpofu"},{"key":"2026043013145408000_ciaf732-B14","doi-asserted-by":"crossref","first-page":"e067765","DOI":"10.1136\/bmjopen-2022-067765","article-title":"INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial","volume":"12","author":"Naidoo","year":"2022","journal-title":"BMJ Open"},{"key":"2026043013145408000_ciaf732-B15","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.1016\/S2352-3018(25)00200-0","article-title":"Fixed-dose combination bictegravir\u2013emtricitabine\u2013tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trial","volume":"13","author":"Naidoo","year":"2026","journal-title":"Lancet HIV"},{"key":"2026043013145408000_ciaf732-B16","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/cid\/ciad267","article-title":"First pharmacokinetic data of tenofovir alafenamide fumarate and tenofovir with dolutegravir or boosted protease inhibitors in African children: a substudy of the CHAPAS-4 trial","volume":"77","author":"Waalewijn","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026043013145408000_ciaf732-B17","doi-asserted-by":"crossref","first-page":"e1893","DOI":"10.1093\/cid\/ciaa1872","article-title":"Tenofovir diphosphate concentrations in dried blood spots from pregnant and postpartum adolescent and young women receiving daily observed pre-exposure prophylaxis in sub-Saharan Africa","volume":"73","author":"Stranix-Chibanda","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026043013145408000_ciaf732-B18","author":"PKanalix FAQ"},{"key":"2026043013145408000_ciaf732-B19","doi-asserted-by":"crossref","first-page":"e1000477","DOI":"10.4172\/2155-6113.1000477","article-title":"Plasma tenofovir concentrations and proximal tubular dysfunction in HIV-infected adults receiving tenofovir in Thailand","volume":"06","author":"Avihingsanon","year":"2015","journal-title":"J AIDS Clin Res"},{"key":"2026043013145408000_ciaf732-B20","author":"US Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS"},{"key":"2026043013145408000_ciaf732-B21","volume-title":"Efficacy, safety, and PK of BIC\/FTC\/TAF in adults with HIV and tuberculosis on rifampicin at week 24","author":"Naidoo","year":"2024"},{"key":"2026043013145408000_ciaf732-B22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1\u2013positive adults","volume":"63","author":"Ruane","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026043013145408000_ciaf732-B23","author":"Custodio"},{"key":"2026043013145408000_ciaf732-B24","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"The Lancet"},{"key":"2026043013145408000_ciaf732-B25","author":"Custodio"},{"key":"2026043013145408000_ciaf732-B26","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/cpt.1115","article-title":"Disease-associated changes in drug transporters may impact the pharmacokinetics and\/or toxicity of drugs: a white paper from the international transporter consortium","volume":"104","author":"Evers","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2026043013145408000_ciaf732-B27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.addr.2016.05.001","article-title":"Role and modulation of drug transporters in HIV-1 therapy","volume":"103","author":"Alam","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"2026043013145408000_ciaf732-B28","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3851\/IMP1648","article-title":"Do activities of cytochrome P450 (CYP) 3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?","volume":"15","author":"Jetter","year":"2010","journal-title":"Antivir Ther"},{"key":"2026043013145408000_ciaf732-B29","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1097\/QAD.0000000000003062","article-title":"Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine\/tenofovir alafenamide vs. emtricitabine\/tenofovir disoproxil fumarate","volume":"35","author":"Yager","year":"2021","journal-title":"AIDS"},{"key":"2026043013145408000_ciaf732-B30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0000000000002354","article-title":"Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following tenofovir alafenamide: the TAF-DBS study","volume":"84","author":"Yager","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026043013145408000_ciaf732-B31","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1093\/cid\/ciae212","article-title":"Tenofovir-diphosphate and emtricitabine-triphosphate adherence benchmarks in dried blood spots for persons with HIV receiving tenofovir alafenamide and emtricitabine\u2013based antiretroviral therapy (QUANTI-TAF)","volume":"79","author":"Coyle","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026043013145408000_ciaf732-B32","author":"Yager"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf732\/66151332\/ciaf732.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/4\/e720\/66151332\/ciaf732.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/4\/e720\/66151332\/ciaf732.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:14:59Z","timestamp":1777569299000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/4\/e720\/8407225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,30]]},"published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf732","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,15]]},"published":{"date-parts":[[2025,12,30]]}}}